SCHEMBL4199153

SCHEMBL4199153

N#Cc1ccc(Nc2cncc(-c3cccc(C(N)=O)c3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.48
ATIC P31939 1/20 0.47
CYP11B2 P19099 1/20 0.46
KCNH2 Q12809 1/20 0.45
SCN10A Q9Y5Y9 1/20 0.45
XDH P47989 4/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
SIRT3 Q9NTG7 1/20 0.44
CCNT1 O60563 1/20 0.44
CCND1 P24385 1/20 0.44
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
CDK7 P50613 1/20 0.44
CDK9 P50750 1/20 0.44
CCNH P51946 1/20 0.44
MNAT1 P51948 1/20 0.44
CDK6 Q00534 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187491 0.85 XDH (0.57) ABL1CYP11B2XDHSIRT2SIRT1
SCHEMBL4199231 0.84 XDH (0.57) ABL1KCNH2XDHSIRT2SIRT1
SCHEMBL4183096 0.82 ABCG2 (0.52) ABL1CYP11B2XDHSLC22A12ABCB1
SCHEMBL4191838 0.81 BRAF (0.61) CYP11B2KCNH2SCN10AXDHSLC22A12
SCHEMBL4147232 0.81 XDH (0.59) ABL1CYP11B2XDHSIRT2SIRT1
SCHEMBL4182331 0.80 SIRT2 (0.71) ABL1CYP11B2XDHSIRT2SIRT1
SCHEMBL4194386 0.80 ABL1 (0.49) ABL1CCNT1CDK9CDK2MKNK1
SCHEMBL4164153 0.80 PARP1 (0.49) ABL1CYP11B2XDHSIRT2SIRT1
SCHEMBL4191929 0.79 XDH (0.61) XDHSIRT2SIRT1SIRT3CCNT1
SCHEMBL4154769 0.79 PARP1 (0.50) ABL1CYP11B2XDHSIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US claimed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP claimed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO claimed
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2020-07-02 US disclosed
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo BROWN DENNIS M (US) 2019-08-20 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20090196912-A1 Pyridinylamines GPC BOTECH AG (DE) 2009-08-06 US disclosed
EP-1789393-A2 PYRIDINYLAMINES GPC Biotech AG (DE) 2007-05-30 EP disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10383847-B2 Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo NEK9, NEK7, NEK3 ABL1 1085/4885ATIC 2150/4885CYP11B2 149/4885
US-20200206188-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 ABL1 1085/4885ATIC 2150/4885CYP11B2 149/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 ABL1 1085/4885ATIC 2150/4885CYP11B2 149/4885
US-20090196912-A1 Pyridinylamines PRNP, PLPBP, SNCA ABL1 2775/4885ATIC 2495/4885CYP11B2 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.